The Technical Analyst
Infinity Pharmaceuticals [INFI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Infinity Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
-52.38% $0.0080
America/New_York / 29 sep 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.726 mill |
| EPS: | -0.440 |
| P/E: | -0.0182 |
| Earnings Date: | Nov 13, 2023 |
| SharesOutstanding: | 90.76 mill |
| Avg Daily Volume: | 3.98 mill |
| RATING 2023-10-27 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0182 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0182 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0051 - 0.0129 ( +/- 230.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-09 | Perkins Adelene Q | Buy | 768 133 | Common Stock |
| 2023-09-12 | Perkins Adelene Q | Sell | 410 196 | Common Stock |
| 2023-09-09 | Perkins Adelene Q | Sell | 768 133 | Restricted Stock Unit |
| 2022-08-02 | Peluso Stephane | Buy | 14 994 | Common Stock |
| 2022-08-02 | Peluso Stephane | Sell | 50 000 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| -16.46 |
| Last 96 transactions |
| Buy: 10 433 668 | Sell: 9 549 867 |
Forecast:
01:40 - $-0.0220
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0080 (-52.38% ) |
| Volume | 2.48 mill |
| Avg. Vol. | 3.98 mill |
| % of Avg. Vol | 62.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INFI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
INFI
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2023-10-16 12:42:00 - Press Release
Infi Deadline Today: Rosen, Skilled Investor Counsel, Encourages Infinity Pharmaceuticals, Inc. Investors To Secure Counsel Before Important October 16 Deadline In Securities Class Action – Infi
New york--(business wire)--why: rosen law firm, a global investor rights law firm, reminds purchasers of securities of infinity pharmaceuticals, inc. (nasdaq: infi) (otc: infiq) between january 5, 2022 and july 24, 2023, both dates inclusive (the “class period”), of the important october 16, 2023 lead plaintiff deadline. so what: if you purchased infinity securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen.
2023-10-16 04:00:00 - Press Release
Final Deadline Today: The Schall Law Firm Encourages Investors In Infinity Pharmaceuticals, Inc. With Losses Of $500,000 To Contact The Firm
Los angeles, ca / accesswire / october 16, 2023 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against infinity pharmaceuticals, inc. ("infinity" or "the company") (nasdaq:infi) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between january 5, 2022 and july 24, 2023, inclusive (the "class period"), are encouraged to contact the firm before october 16, 2023.
2023-10-11 23:45:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Infinity Pharmaceuticals, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles, ca / accesswire / october 11, 2023 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against infinity pharmaceuticals, inc. ("infinity" or "the company") (nasdaq:infi) for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between january 5, 2022 and july 24, 2023, inclusive (the "class period"), are encouraged to contact the firm before october 16, 2023.
2023-10-11 04:00:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Infinity Pharmaceuticals, Inc. With Losses Of $500,000 To Contact The Firm
Los angeles, ca / accesswire / october 11, 2023 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against infinity pharmaceuticals, inc. ("infinity" or "the company") (nasdaq:infi) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between january 5, 2022 and july 24, 2023, inclusive (the "class period"), are encouraged to contact the firm before october 16, 2023.
2023-10-10 05:00:00 - Press Release
Final Deadline Tomorrow: The Schall Law Firm Encourages Investors In Infinity Pharmaceuticals, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles, ca / accesswire / october 10, 2023 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against infinity pharmaceuticals, inc. ("infinity" or "the company") (nasdaq:infi) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between january 5, 2022 and july 24, 2023, inclusive (the "class period"), are encouraged to contact the firm before october 16, 2023.
Latest News
2023-08-08 07:34:57 - InvestorPlace
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?
Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.
2023-06-15 12:08:00 - Business Wire
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.
2023-03-28 19:04:55 - Zacks Investment Research
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-28 11:29:09 - Zacks Investment Research
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-03-14 08:02:44 - Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2022-11-17 11:17:46 - Zacks Investment Research
Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-11-14 11:24:03 - Seeking Alpha
Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.
2022-11-07 08:25:00 - Business Wire
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
2022-08-09 23:03:15 - Seeking Alpha
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript
Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Senior Executive Coordinator Conference Call Participants Edward Tenthoff - Piper Sandler Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Second Quarter 2022 Financial Results and Business Update.
2022-05-17 08:35:00 - Business Wire
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, May 24th